Gert J. Ossenkoppele

P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.

E. D. de Vries, E. Vellenga, G. Ossenkoppele, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.

K. Döhner, R. Schlenk, H. Döhner, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).

E. Vellenga, M. Jongen‐Lavrencic, J. Passweg, 2012, Blood.

Acute myeloid leukemia

H. Kantarjian, C. Willman, F. Giles, 2018, Methods in Molecular Biology.

Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.

R. Brand, G. Ossenkoppele, J. Cornelissen, 2005, Haematologica.

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

W. M. Smit, M. Kersten, P. Sonneveld, 2008, Blood.